Ovid Therapeutics Inc. - COMMON STOCK (OVID)

Historical Holders from Q2 2017 to Q4 2025

Type / Class
Equity / COMMON STOCK
Symbol
OVID on Nasdaq
Shares outstanding
130,255,320
Price per share
$1.63
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
36,211,271
Total reported value
$47,075,130
% of total 13F portfolios
0%
Share change
+264,490
Value change
+$6,613,805
Avg buy value change
+0%
Avg sell value change
-0%
Number of holders
80
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Ovid Therapeutics Inc. - COMMON STOCK (OVID) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
RA CAPITAL MANAGEMENT, L.P. 9.9% $17,635,448 13,259,735 RA Capital Management, L.P. 11 Dec 2025
Affinity Asset Advisors, LLC 9% $16,158,391 12,149,166 Affinity Asset Advisors, LLC 11 Dec 2025
TAKEDA PHARMACEUTICAL CO LTD 12% $13,172,994 8,781,996 Takeda Pharmaceutical Company Limited 08 Dec 2025
FEDERATED HERMES, INC. 5.9% $12,611,581 7,737,166 Federated Hermes, Inc. 31 Dec 2025
JANUS HENDERSON GROUP PLC 10% $10,671,171 7,114,114 JANUS HENDERSON GROUP PLC 28 Nov 2025
Point72 Asset Management, L.P. 5.1% $11,099,895 6,727,209 Point72 Asset Management, L.P. 02 Jan 2026
Madison Avenue Partners, LP 4% $889,649 2,852,352 Madison Avenue Partners, LP 31 Dec 2024
BlackRock, Inc. 1.9% $397,013 1,369,010 BlackRock, Inc. 30 Jun 2025
Rubric Capital Management LP 0.67% $138,775 478,533 Rubric Capital Management LP 30 Jun 2025
As of 30 Sep 2025, Ovid Therapeutics Inc. - COMMON STOCK (OVID) has 80 institutional shareholders filing 13F forms. They hold 36,211,271 shares. of 130,255,320 outstanding shares (28%) .

Top 25 institutional shareholders own 25% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
TAKEDA PHARMACEUTICAL CO LTD 5.8% 7,531,996 0% 60% $9,791,595
VANGUARD GROUP INC 2.2% 2,820,813 +7% 0% $3,667,058
Affinity Asset Advisors, LLC 2% 2,650,000 +297% 0.32% $3,445,000
ACADIAN ASSET MANAGEMENT LLC 1.8% 2,286,505 +8.5% 0.01% $2,971,000
RENAISSANCE TECHNOLOGIES LLC 1.5% 2,018,024 -3.7% 0% $2,623,431
Sio Capital Management, LLC 1.1% 1,427,495 -36% 0.47% $1,855,744
Driehaus Capital Management LLC 1.1% 1,400,191 0% 0.01% $1,820,248
ADAGE CAPITAL PARTNERS GP, L.L.C. 1% 1,350,000 +17% 0% $1,755,000
KENNEDY CAPITAL MANAGEMENT LLC 0.85% 1,106,638 -26% 0.03% $1,438,629
Ikarian Capital, LLC 0.84% 1,095,574 0.32% $1,424,247
MILLENNIUM MANAGEMENT LLC 0.76% 986,293 -6.3% 0% $1,282,181
Assenagon Asset Management S.A. 0.71% 924,576 +112% 0% $1,201,949
Schonfeld Strategic Advisors LLC 0.68% 883,154 0.01% $1,148,098
MARSHALL WACE, LLP 0.6% 783,653 +376% 0% $1,018,751
WELLS FARGO & COMPANY/MN 0.56% 730,716 -4.2% 0% $949,932
GEODE CAPITAL MANAGEMENT, LLC 0.5% 648,020 +0.73% 0% $842,631
Balyasny Asset Management L.P. 0.48% 625,000 0% $812,500
BlackRock, Inc. 0.47% 611,315 -55% 0% $794,710
Walleye Capital LLC 0.46% 596,717 0.01% $775,732
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.45% 589,094 +156% 0% $765,822
BOOTHBAY FUND MANAGEMENT, LLC 0.37% 486,877 0.02% $632,940
CITADEL ADVISORS LLC 0.31% 405,382 0% $526,997
SIMPLEX TRADING, LLC 0.3% 387,512 0.01% $503,000
BANK OF AMERICA CORP /DE/ 0.28% 362,707 +2333% 0% $471,519
TWO SIGMA INVESTMENTS, LP 0.26% 341,134 0% $443,474

Institutional Holders of Ovid Therapeutics Inc. - COMMON STOCK (OVID) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (% of par) Investors
2025 Q4 628,019 $1,023,671 -$499,688 163% 2
2025 Q3 36,211,271 $47,075,130 +$6,613,805 130% 80
2025 Q2 35,963,686 $11,861,338 -$3,392,036 32.99% 69
2025 Q1 46,399,305 $14,470,049 -$2,823,887 31.19% 81
2024 Q4 47,565,663 $44,391,458 +$933,721 93.37% 80
2024 Q3 46,326,650 $54,660,766 -$2,312,504 118% 76
2024 Q2 38,490,729 $29,602,958 -$20,868,723 76.92% 72
2024 Q1 50,111,416 $152,838,666 -$4,521,523 305% 80
2023 Q4 7,558,793 $24,339,313 -$57,584 322% 2
2023 Q3 42,343,665 $162,597,735 +$5,682,269 384% 64
2023 Q2 41,007,449 $134,502,709 +$8,714,594 328% 69
2023 Q1 38,694,424 $99,783,463 +$650,217 258% 60
2022 Q4 38,555,681 $71,711,529 +$2,583,303 186% 56
2022 Q3 33,884,019 $62,344,293 +$1,735,945 184.02% 50
2022 Q2 34,197,216 $73,522,307 -$3,001,295 215% 51
2022 Q1 35,129,902 $110,306,198 +$3,431,136 314% 60
2021 Q4 33,993,138 $109,111,202 +$1,312,258 321% 63
2021 Q3 33,589,655 $112,863,212 +$498,942 336% 70
2021 Q2 33,196,688 $129,797,427 -$11,484,092 391% 77
2021 Q1 32,755,130 $131,671,613 +$41,031,412 401.92% 84
2020 Q4 24,830,644 $57,358,129 -$5,602,917 230.99% 73
2020 Q3 25,114,493 $144,162,828 +$11,161,450 574.01% 90
2020 Q2 19,727,290 $145,398,711 +$45,823,549 737% 76
2020 Q1 13,602,580 $40,539,209 -$7,096,587 298.06% 52
2019 Q4 17,742,744 $73,634,290 +$38,177,804 415% 57
2019 Q3 8,206,512 $26,588,025 -$5,117,370 323.98% 37
2019 Q2 10,118,552 $18,720,869 -$3,455,299 185.04% 32
2019 Q1 12,276,057 $21,733,954 +$9,093,019 177.09% 46
2018 Q4 6,835,729 $16,540,605 -$8,551,955 241.95% 46
2018 Q3 7,392,582 $41,915,393 -$3,041,259 567.01% 47
2018 Q2 7,651,267 $59,676,116 -$351,480 780.06% 45
2018 Q1 7,048,747 $49,828,303 -$9,280,074 706.8% 48
2017 Q4 7,821,975 $77,207,294 +$5,974,372 987.02% 48
2017 Q3 7,221,932 $61,486,225 -$6,770,504 856.91% 42
2017 Q2 7,962,804 $81,479,560 +$81,479,413 1,048.87% 42